Trials / Completed
CompletedNCT06048887
Single and Multiple-Ascending Dose Study of CRN04894 in Healthy Volunteers
A Double-blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN04894 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Crinetics Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
A Phase 1, first-in-human, double-blind, randomized, placebo-controlled study to evaluate the safety of CRN04894 in healthy volunteers as well as the relationship between exposure and pharmacodynamic (PD) parameters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CRN04894 Oral Solution | CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist. |
| DRUG | Placebo Oral Solution | Placebo |
Timeline
- Start date
- 2020-12-18
- Primary completion
- 2022-04-11
- Completion
- 2022-04-11
- First posted
- 2023-09-21
- Last updated
- 2023-09-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06048887. Inclusion in this directory is not an endorsement.